| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of Pathology,
*
Tumor Biology,
and Oncology,
¶
The Norwegian Radium Hospital, Oslo, Norway; Pubgene Inc.,
Oslo, Norway; and the Department of Academic Haematology and Cytogenetics,
Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
Splenic marginal zone lymphoma (SMZL) is a lymphoma type of putative marginal zone B-cell origin. No specific genetic alterations have yet been demonstrated in SMZL. Clinically, SMZL is a low-grade B-cell non-Hodgkin lymphoma. However, the presence of p53 mutation, 7q22–7q32 deletion or the absence of somatic hypermutations of immunoglobulin genes has been correlated with a worse prognosis. In this study, we analyzed genome-wide gene expression of 24 cases of SMZL using the microarray technique. The AP-1 transcription factors c-jun, junD, junB, and c-fos as well as Notch2 were found to be specifically up-regulated. These data were confirmed by real-time PCR and immunohistochemical staining of tissue sections. The absence of concordant high expression of the MAP kinases, the signaling cascade leading to AP-1 up-regulation, suggests autoregulation of the AP-1 transcription factors and an important role in SMZL oncogenesis. High expression of Notch2, a transcription factor that induces marginal zone B-cell differentiation, is highly suggestive for a marginal zone B-cell origin of SMZL. In addition, SMZL with the 7q deletion showed high expression of TGF-ß1 and low expression of the DNA helicase XPB, a crucial part of the nucleotide excision repair complex, possibly explaining the more aggressive clinical course of those cases.
This article has been cited by other articles:
 |
|
 |
|
  G. Troen, I. Wlodarska, A. Warsame, S. Hernandez Llodra, C. De Wolf-Peeters, and J. Delabie NOTCH2 mutations in marginal zone lymphoma Haematologica, July 1, 2008; 93(7): 1107 - 1109. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Marden, Y. Zhang, F. D. Oakley, W. Zhou, M. Luo, H. P. Jia, P. B. McCray Jr., M. Yaniv, J. B. Weitzman, and J. F. Engelhardt JunD Protects the Liver from Ischemia/Reperfusion Injury by Dampening AP-1 Transcriptional Activation J. Biol. Chem., March 14, 2008; 283(11): 6687 - 6695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. LeBrun, T. Baetz, C. Foster, P. Farmer, R. Sidhu, H. Guo, K. Harrison, R. Somogyi, L. D. Greller, and H. Feilotter Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Clin. Cancer Res., January 15, 2008; 14(2): 478 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sakhinia, C. Glennie, J. A. Hoyland, L. P. Menasce, G. Brady, C. Miller, J. A. Radford, and R. J. Byers Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling Blood, May 1, 2007; 109(9): 3922 - 3928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Y.-Y. Hsu, P. B. Johnston, K. A. Burke, and Y. Zhao The Expression of CD30 in Anaplastic Large Cell Lymphoma Is Regulated by Nucleophosmin-Anaplastic Lymphoma Kinase-Mediated JunB Level in a Cell Type-Specific Manner. Cancer Res., September 15, 2006; 66(18): 9002 - 9008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ruiz-Ballesteros, M. Mollejo, A. Rodriguez, F. I. Camacho, P. Algara, N. Martinez, M. Pollan, A. Sanchez-Aguilera, J. Menarguez, E. Campo, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis Blood, September 1, 2005; 106(5): 1831 - 1838. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
